Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the most effective tumor immunotherapy available. Although allo-HSCT provides beneficial graft-versus-tumor effects, graft versus host disease (GVHD) is the primary source of morbidity and mortality after HSCT. GVHD can be classified as acute or chronic, based on the clinical, laboratorial and histological presentation. The…